研究表明：利用大劑量的諾和諾德公司的抗凝血藥來治療非血友病的患者，比如出血中風，外傷，手術，器官移植等，可能會提高心臟病發(fā)作的風險。

The drug, NovoSeven, is a genetically engineered version of factor VII, a key protein missing in some people with the bleeding disease hemophilia.

Some doctors prescribe the drug in "off-label" use to stop unwanted bleeding associated with stroke, trauma, surgery, transplantation and other medical conditions. Doctors may prescribe any approved drug for any reason they want to.